HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
10 09 2019
10 09 2019
Historique:
received:
24
06
2019
accepted:
09
07
2019
entrez:
6
9
2019
pubmed:
6
9
2019
medline:
4
9
2020
Statut:
ppublish
Résumé
HLA haploidentical hematopoietic cell transplantation (haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) is an alternative strategy when a matched sibling donor (MSD) is not available. We performed a systematic review and meta-analysis to compare the outcomes of MSD vs haplo-HCT. Eleven studies (1410 haplo-HCT and 6396 MSD recipients) were meta-analyzed. All studies were retrospective and high quality, and 9 were multicenter. Haplo-HCT was associated with ~50% lower risk of chronic graft-versus-host disease (GVHD) (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.41-0.74), but higher risk of nonrelapse mortality (HR, 1.36; 95% CI, 1.12-1.66). Relapse, survival, acute GVHD, and GVHD-free relapse-free survival were not significantly different between the groups. Deciphering the relative contribution of PT-Cy and HLA disparity to the observed outcome differences between the groups requires further research.
Identifiants
pubmed: 31484635
pii: bloodadvances.2019000614
doi: 10.1182/bloodadvances.2019000614
pmc: PMC6737418
doi:
Substances chimiques
HLA Antigens
0
Cyclophosphamide
8N3DW7272P
Types de publication
Comparative Study
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2581-2585Informations de copyright
© 2019 by The American Society of Hematology.
Références
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Health Technol Assess. 2003;7(27):iii-x, 1-173
pubmed: 14499048
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Biol Blood Marrow Transplant. 2008 Nov;14(11):1279-87
pubmed: 18940683
J R Stat Soc Ser A Stat Soc. 2009 Jan;172(1):137-159
pubmed: 19381330
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Res Synth Methods. 2010 Apr;1(2):112-25
pubmed: 26061377
J Clin Oncol. 2015 Oct 1;33(28):3152-61
pubmed: 26261255
Biol Blood Marrow Transplant. 2016 Jan;22(1):125-33
pubmed: 26359881
Biol Blood Marrow Transplant. 2016 Aug;22(8):1403-1409
pubmed: 27095692
Leukemia. 2016 Oct;30(10):2086-2089
pubmed: 27146790
J Clin Oncol. 2016 Sep 10;34(26):3141-9
pubmed: 27269951
J Clin Oncol. 2017 Sep 10;35(26):3002-3009
pubmed: 28644773
J Clin Oncol. 2017 Oct 20;35(30):3425-3432
pubmed: 28846465
Biometrics. 2018 Sep;74(3):785-794
pubmed: 29141096
Bone Marrow Transplant. 2018 Apr;53(4):400-409
pubmed: 29330405
Biol Blood Marrow Transplant. 2018 Jul;24(7):1449-1454
pubmed: 29448057
Blood Adv. 2018 Jun 12;2(11):1180-1186
pubmed: 29794073
Blood Adv. 2019 Feb 12;3(3):360-369
pubmed: 30723110
Lancet Haematol. 2019 Mar;6(3):e132-e143
pubmed: 30824040
Haematologica. 2019 May 17;:null
pubmed: 31101756
Biol Blood Marrow Transplant. 2019 May 25;:null
pubmed: 31132455
Am J Med. 1980 Aug;69(2):204-17
pubmed: 6996481
J Clin Oncol. 1997 May;15(5):1767-77
pubmed: 9164184
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563